Companies · Pharma

Levo Therapeutics, Inc.

SKOKIE · Pharma · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Levo Therapeutics, Inc. — recommendation, valuation, rhythm, risks.
$86.5M
Total raised · real
2
Rounds
0.9×
Latest step-up
Top 12%
Sector rank · raised
Series C
Latest stage · inferred · Wed Sep 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Levo Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.70× the median modeled value of Series C Pharma companies in 2019–2021 (7 peers) — value vs value, same stage and era.
  • Within the normal band (70% of peer median) for its niche.
Dormant
  • Last raise 6.8 yr ago; this sector typically re-raises about every 16 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Levo Therapeutics, Inc. is one of 310 Pharma companies tracked from SKOKIE. By capital raised it ranks in the upper tier (ahead of 89% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2015
Year incorporated
2019-09-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries C · 2017-08-04 Raised $47M (real) Modeled valuation $1.6B (est)$47M$1.6BSeries C2017Series C · 2019-09-04 Raised $40M (real) Modeled valuation $1.4B (est)$40M$1.4BSeries C2019+$40MCumulative $87M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$46.5M · 2017
Series C extension$40.0M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.

Modeled valuation trajectory
$1.4B
Base estimate est.
$129.9M
Conservative case
$3.7B
Upside case
$266.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series C · modeled $1.6B · 2017-08-042017Series C · modeled $1.4B · 2019-09-042019
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
66%
Survival probability
49% low · 76% high
1.42×/yr
Annual markup
1.62×/yr upside case
6.0 yr
Elapsed time used
6.8 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
25 mo
Avg between rounds
$41.5M/yr
Capital velocity
8.9 yr
On record since
2017
First round
2
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 14× above median
This company$86.5M
Sector median$6.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.8× of median
This company$40.0M
Sector median$49.7M
Modeled value — vs sector median (estimate, all stages) 22× above median
This company$1.4B
Sector median$62.5M

Raised more than 89% of sector peers (real $). Modeled value above 92% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #6 of 7.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Ansun Biopharma, Inc. · Series C Raised $195.1M · modeled $3.5B (est)Integrated Oncology Network Holdco, LLC · Series C Raised $69.9M · modeled $2.5B (est)Tallac Therapeutics, Inc. · Series C Raised $61.6M · modeled $2.2B (est)Elevation Oncology, Inc. · Series C Raised $70.5M · modeled $2.0B (est)CERo Therapeutics, Inc. · Series C Raised $44.6M · modeled $1.5B (est)Interline Therapeutics, Inc. · Series C Raised $92.6M · modeled $1.1B (est)Levo Therapeutics, Inc. (this company) Raised $86.5M · modeled $1.4B (est)Levo Therapeutics, Inc.
CompanyStageRaised · realValue · estvs peer med.
Ansun Biopharma, Inc.Series C$195.1M$3.5B1.74×
Integrated Oncology Network Holdco, LLCSeries C$69.9M$2.5B1.22×
Tallac Therapeutics, Inc.Series C$61.6M$2.2B1.07×
Elevation Oncology, Inc.Series C$70.5M$2.0B1.00×
CERo Therapeutics, Inc.Series C$44.6M$1.5B0.75×
Levo Therapeutics, Inc. this companySeries C$86.5M$1.4B0.70×
Interline Therapeutics, Inc.Series C$92.6M$1.1B0.54×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$46.5M2017-08-04$310.2M$1.6B90%
Series C$40.0M2019-09-04$266.7M$1.4B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$46.5M2017-08-04
    • First recorded raise — entered as Series C.
    • 5 investors on this round.
  2. Series C$40.0M2019-09-04
    • Raised again after 25 mo — slower than the ~16 mo sector norm.
    • Round roughly the size of the prior one.
    • 4 investors on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~25mo cadence
$40.0M
Modeled next size est.range $40.0M$64.0M
0.9×
Last step-up
$41.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
MICHAEL DYBBS4 other2017-08
Daniel Welch2017-08
Sara Brownstein2017-08
Sara Cotter2017-08
Steven Ryder2017-08
Terrence Kearney2017-08
Registry & provenance

Levo Therapeutics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1793935
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
INCOG BioPharma Services, Inc.PharmaSeries C$86.6M$392.7Msame sector · same stage
Averna Therapeutics Inc.PharmaSeries C$85.0M$805.8Msame sector · same stage
Indapta Therapeutics Inc.PharmaSeries C$84.4M$289.9Msame sector · same stage
Interline Therapeutics, Inc.PharmaSeries C$92.6M$1.1Bsame sector · same stage
Soleno Therapeutics IncPharmaSeries C$98.6M$680.6Msame sector · same stage
Pheast Therapeutics, Inc.PharmaSeries C$99.8M$138.6Msame sector · same stage
Ovid Therapeutics Inc.PharmaSeries C$105.9M$907.5Msame sector · same stage
Elevation Oncology, Inc.PharmaSeries C$70.5M$2.0Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Convelo Therapeutics, Inc.PharmaSeries A$113.3M85%
Nuo Therapeutics, Inc.PharmaSeries B$3.6M85%
Nia Therapeutics, Inc.PharmaSeries B$357.8M83%
Luma Therapeutics, Inc.PharmaSeed$77.9M83%
Chaperone Therapeutics, Inc.PharmaPre-Seed$21.6M83%
Cyrano Therapeutics, Inc.PharmaSeries A$108.4M82%
Cognito Therapeutics Group, Inc.PharmaSeries D+$1.7B82%
CO-D Therapeutics, Inc.PharmaPre-Seed$20.2M82%
Frequently asked
How much funding has Levo Therapeutics, Inc. raised?
Levo Therapeutics, Inc. has raised approximately $86.5M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Levo Therapeutics, Inc.'s estimated valuation?
Provath's modeled valuation for Levo Therapeutics, Inc. is approximately $1.4B (modeled range $129.9M–$3.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Levo Therapeutics, Inc. at?
Levo Therapeutics, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Sep 04.
What does Levo Therapeutics, Inc. do and where is it based?
Levo Therapeutics, Inc. operates in the Pharma sector, based in SKOKIE.
Explore related

See where Levo Therapeutics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Levo Therapeutics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.